학술논문
Serological response following BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccination in haematopoietic stem cell transplantation patients.
Document Type
Article
Author
Attolico, Immacolata; Tarantini, Francesco; Carluccio, Paola; Schifone, Claudia Pia; Delia, Mario; Gagliardi, Vito Pier; Perrone, Tommasina; Gaudio, Francesco; Longo, Chiara; Giordano, Annamaria; Sgherza, Nicola; Curci, Paola; Rizzi, Rita; Ricco, Alessandra; Russo Rossi, Antonella; Albano, Francesco; Larocca, Angela Maria Vittoria; Vimercati, Luigi; Tafuri, Silvio; Musto, Pellegrino
Source
Subject
*HEMATOPOIETIC stem cell transplantation
*MYELOFIBROSIS
*SARS-CoV-2
*CHRONIC leukemia
*VACCINATION
*COVID-19 vaccines
*
*
*
*
*
Language
ISSN
0007-1048
Abstract
In G1, all patients, allogeneic recipients and autologous recipients had significantly lower antibody levels than HC, whereas no differences were found in G2. Among the patients vaccinated >5 years after HSCT, allogeneic recipients had antibody titres comparable to HC; in contrast, autologous recipients had significantly lower titres than HC. Keywords: stem cell transplantation; severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination; seroconversion EN stem cell transplantation severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination seroconversion 928 931 4 02/14/22 20220215 NES 220215 Adult patients with haematological malignancies (HM) and coronavirus disease 2019 (COVID-19) have a higher mortality than healthy subjects.1-3 In particular, haematopoietic stem-cell transplantation (HSCT) recipients have a poor prognosis,4,5 strongly supporting the role of vaccination. Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients. [Extracted from the article]